News | April 21, 2008

Internists to Get Fresh View of Evidence-Based Medicine

April 22, 2008 - Balancing evidence-based medicine and point-of-care testing for improved supervision efficiency and patient satisfaction, with time constraints, complex care networks and complicated trial findings hinder success will be discussed at "Managing CVD," a seminar for internists, to be held on May 14, 2008, at the Renaissance Grand Ballroom North in Washington, DC.

The continuing medical education (CME) program includes a review of the most current clinical information for overseeing hypertensive patient care given by Michael J. Bloch, MD, Associate Professor, Internal Medicine and Cardiology, University of Nevada School of Medicine, and Medical Director, St. Mary's Risk Reduction Center, Reno.

The program will also address internists with a fresh grasp of heart failure in association with obesity, hypertension and coronary artery disease as well as anticoagulant initiatives.

"The key lesson of recent cholesterol clinical trials is only partly that we should be treating to lower LDL targets; as important is evaluating a variety of different non-lipid risk factors in determining patients appropriate for medical therapy," said one of the speakers, Benjamin J. Ansell, M.D., FACP, FACC, associate professor, Medicine/Cardiology, and co-director, Cholesterol, Hypertension and Atherosclerosis Management Program, UCLA David Geffen School of Medicine.

For more information: www.medavera.com and www.managingcvd.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init